SlideShare ist ein Scribd-Unternehmen logo
1 von 23
The views of patients and carers
   involved in the development of
     NICE technology appraisals

Lizzie Amis
Patient and Public Involvement Programme
National Institute for Health and Clinical Excellence (NICE)
Outline of presentation

• Patient/carer involvement in the appraisals process
• The Patient Expert process at NICE
• Patient Expert questionnaire project:
  –   Why we did it
  –   What we did
  –   What we found, including sample comments
  –   Next steps
How can patients/carers
   contribute to a NICE appraisal?
• National patient organisations can:
  – Comment on draft documents
  – Submit written evidence
  – Nominate Patient Experts


• Individuals can:
  – Be a lay member on the Appraisal Committee
  – Attend the committee meeting as a Patient Expert
How do Patient Experts contribute?

• Attend first Appraisal Committee meeting of each topic
• Complete written statement before meeting
• Present evidence and comment from patient
  perspective on:
  – Experiences and views
  – Benefits/ advantages of the therapy
  – Downsides/ concerns of the therapy
Why did we do this project?

• Surveyed Patient Experts a few years ago (Phase 1)
• Made changes based on findings:
  – ‘Lay Leads’ role
  – Improved internal processes
  – Better documentation

• Wanted to see whether:
  – changes had made a difference
  – there were further possible improvements
Patient Expert Questionnaire:
            what did we do?
Phase 1
• Developed a questionnaire asking Patient Experts about
  their involvement in a NICE appraisal
• Piloted the questionnaire
• Sent to all Patient Experts who attended a committee
  meeting between May ’06 and Oct ’07
• Two rounds of chasing for responses

Phase 2
• We repeated the process with those who attended
  (July ‘10 – Dec ‘11) – but using SurveyMonkeyTM
Patient Expert Questionnaire:
       what did we ask about?
• About you
• Information and support before the day
• Practical arrangements and support on the day
• Experiences during the committee meeting
• After the meeting
• What is most important to you? (Phase 2)


                                       Text giving explanations
• Anything else?
What we found 1 –
  who replied?
Who replied?




  Partial
responses
 5% [n/a]
Who replied – by type of Expert?
What we found 2 –
Patient Experts’ understanding
   of the committee meeting
Reported understanding of committee
questions, presentation and discussion
Free text comments –
understanding of committee meeting
Positive
• “The meeting was well organised and well run.”
• “There was opportunity to discuss angles of my
  submission and re-affirm my position on certain aspects.”

Concerns
• “I felt totally out of my depth and excluded when the
  technical/statistical information was shared.”
• “A lot of the presentation went over my head. There was a
  lot of discussion [...] which didn’t mean very much to me.”
What we found 3 –
  Patient Experts’ opinions on their
involvement in the committee meeting
Patient Expert views on their
involvement in the committee meeting
                                 24%
Comments – Patient involvement
        in committee meeting
Positive
• “Felt my presence worthwhile not just tolerated. My contribution
  listened to with interest. Treated with consideration.”
• “I think my comments were taken seriously […] I was given
  time and opportunity to contribute at several stages of the
  meeting.”

Concerns
• “The real issue is whether patients are taken seriously and
  listened to in the meeting.”
• “There was patient experience as far as goes side effects etc,
  however the patient experience is far more than this...”
What we found 4 –
What is most important to you?
What is considered most important by
 our patient experts? (Phase 2 only)

Ranked in priority order:
1.   Having the opportunity to raise the issues I felt relevant
2.   Feeling that my contribution made a difference
3.   Contact and support before the committee meeting
4.   Understanding the committee discussions

(A further six criteria were all less important)
What we found 5 –
Overall experience of
 committee meeting
Overall experience
      of committee meeting

19%
Comments – Overall experience
Positive
• “I thought it was a very well-thought out process, and
  feel honoured to have been a part of it.”
• “I feel the Patient Expert process works very well. The
  only improvement would be to have a better
  understanding of the technology jargon.”

Concerns
• “The process needs to be made more human and
  accessible.”
• “Patient organisations by and large know how NICE
  works […] The question is whether NICE […] has
  developed a similar understanding of patients and
  patient organisations.”
Next Steps

•   Complete written report
•   Identify further areas for improvement
•   Present findings at conferences and in journals
•   Design exit survey with patients for continual,
    ongoing monitoring
Contact details & more info

Lizzie Amis
PPIP Programme Manager
lizzie.amis@nice.org.uk or +44 (0) 20 7045 2056



Patient and Public Involvement at NICE:
http://www.nice.org.uk/getinvolved/patientsandpublic/patientan

Weitere ähnliche Inhalte

Ähnlich wie The views of patients and carers involved in the development of NICE technology appraisals

A2 Understanding victims' needs: assessment, quality standards and integratio...
A2 Understanding victims' needs: assessment, quality standards and integratio...A2 Understanding victims' needs: assessment, quality standards and integratio...
A2 Understanding victims' needs: assessment, quality standards and integratio...VSE 2016
 
Understanding patient and stakeholder needs alongside the patient journey - ...
Understanding patient and stakeholder needs alongside the patient journey -  ...Understanding patient and stakeholder needs alongside the patient journey -  ...
Understanding patient and stakeholder needs alongside the patient journey - ...د حاتم البيطار
 
Public & patient engagement session 2
Public & patient engagement session 2Public & patient engagement session 2
Public & patient engagement session 2PJDenton
 
Good practice in evaluation research
Good practice in evaluation researchGood practice in evaluation research
Good practice in evaluation researchQSR International
 
Exercise programs for people with dementia: What's the evidence?
Exercise programs for people with dementia: What's the evidence?Exercise programs for people with dementia: What's the evidence?
Exercise programs for people with dementia: What's the evidence?Health Evidence™
 
Bedfordshire CCG- Involving service users and carers in the selection of new ...
Bedfordshire CCG- Involving service users and carers in the selection of new ...Bedfordshire CCG- Involving service users and carers in the selection of new ...
Bedfordshire CCG- Involving service users and carers in the selection of new ...RuthEvansPEN
 
Vicky Pelka's Training Session On Impact Evaluation
Vicky Pelka's Training Session On Impact EvaluationVicky Pelka's Training Session On Impact Evaluation
Vicky Pelka's Training Session On Impact EvaluationJosh Chandler
 
Trust workshop presentations combined
Trust workshop presentations combinedTrust workshop presentations combined
Trust workshop presentations combinedChris Jacob
 
Florida National University Importance of Evidence Based Practice Discussion....
Florida National University Importance of Evidence Based Practice Discussion....Florida National University Importance of Evidence Based Practice Discussion....
Florida National University Importance of Evidence Based Practice Discussion....write4
 
Public & patient engagement session 1
Public & patient engagement session 1Public & patient engagement session 1
Public & patient engagement session 1PJDenton
 
A service improvement focused on frailty using an R&D approach, pop up uni, 3...
A service improvement focused on frailty using an R&D approach, pop up uni, 3...A service improvement focused on frailty using an R&D approach, pop up uni, 3...
A service improvement focused on frailty using an R&D approach, pop up uni, 3...NHS England
 
Organizational Capacity-Building Series - Session 6: Program Evaluation
Organizational Capacity-Building Series - Session 6: Program EvaluationOrganizational Capacity-Building Series - Session 6: Program Evaluation
Organizational Capacity-Building Series - Session 6: Program EvaluationINGENAES
 
Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...
Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...
Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...Paul Gallant
 
Assessing Readiness to Engage (Jan 2021)
Assessing Readiness to Engage (Jan 2021)Assessing Readiness to Engage (Jan 2021)
Assessing Readiness to Engage (Jan 2021)CHICommunications
 
Scrutiny as a critical friend wlga presentation
Scrutiny as a critical friend wlga presentationScrutiny as a critical friend wlga presentation
Scrutiny as a critical friend wlga presentationDave Mckenna
 

Ähnlich wie The views of patients and carers involved in the development of NICE technology appraisals (20)

In-Depth Interviews: Techniques and Best Practices
In-Depth Interviews: Techniques and Best PracticesIn-Depth Interviews: Techniques and Best Practices
In-Depth Interviews: Techniques and Best Practices
 
A2 Understanding victims' needs: assessment, quality standards and integratio...
A2 Understanding victims' needs: assessment, quality standards and integratio...A2 Understanding victims' needs: assessment, quality standards and integratio...
A2 Understanding victims' needs: assessment, quality standards and integratio...
 
Understanding patient and stakeholder needs alongside the patient journey - ...
Understanding patient and stakeholder needs alongside the patient journey -  ...Understanding patient and stakeholder needs alongside the patient journey -  ...
Understanding patient and stakeholder needs alongside the patient journey - ...
 
Public & patient engagement session 2
Public & patient engagement session 2Public & patient engagement session 2
Public & patient engagement session 2
 
Good practice in evaluation research
Good practice in evaluation researchGood practice in evaluation research
Good practice in evaluation research
 
CareSearch, NSAP and PCOC: Evidence, standards and quality, but what does it ...
CareSearch, NSAP and PCOC: Evidence, standards and quality, but what does it ...CareSearch, NSAP and PCOC: Evidence, standards and quality, but what does it ...
CareSearch, NSAP and PCOC: Evidence, standards and quality, but what does it ...
 
Exercise programs for people with dementia: What's the evidence?
Exercise programs for people with dementia: What's the evidence?Exercise programs for people with dementia: What's the evidence?
Exercise programs for people with dementia: What's the evidence?
 
Bedfordshire CCG- Involving service users and carers in the selection of new ...
Bedfordshire CCG- Involving service users and carers in the selection of new ...Bedfordshire CCG- Involving service users and carers in the selection of new ...
Bedfordshire CCG- Involving service users and carers in the selection of new ...
 
Vicky Pelka's Training Session On Impact Evaluation
Vicky Pelka's Training Session On Impact EvaluationVicky Pelka's Training Session On Impact Evaluation
Vicky Pelka's Training Session On Impact Evaluation
 
Trust workshop presentations combined
Trust workshop presentations combinedTrust workshop presentations combined
Trust workshop presentations combined
 
Florida National University Importance of Evidence Based Practice Discussion....
Florida National University Importance of Evidence Based Practice Discussion....Florida National University Importance of Evidence Based Practice Discussion....
Florida National University Importance of Evidence Based Practice Discussion....
 
Public & patient engagement session 1
Public & patient engagement session 1Public & patient engagement session 1
Public & patient engagement session 1
 
A service improvement focused on frailty using an R&D approach, pop up uni, 3...
A service improvement focused on frailty using an R&D approach, pop up uni, 3...A service improvement focused on frailty using an R&D approach, pop up uni, 3...
A service improvement focused on frailty using an R&D approach, pop up uni, 3...
 
Organizational Capacity-Building Series - Session 6: Program Evaluation
Organizational Capacity-Building Series - Session 6: Program EvaluationOrganizational Capacity-Building Series - Session 6: Program Evaluation
Organizational Capacity-Building Series - Session 6: Program Evaluation
 
Self management in chronic disease project workshop
Self management in chronic disease project workshopSelf management in chronic disease project workshop
Self management in chronic disease project workshop
 
Rapid Review Methods in a COVID-19 World
Rapid Review Methods in a COVID-19 WorldRapid Review Methods in a COVID-19 World
Rapid Review Methods in a COVID-19 World
 
Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...
Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...
Better Healthcare Through Community and Stakeholder Engagement, 2015 Webinar ...
 
Assessing Readiness to Engage (Jan 2021)
Assessing Readiness to Engage (Jan 2021)Assessing Readiness to Engage (Jan 2021)
Assessing Readiness to Engage (Jan 2021)
 
Scrutiny as a critical friend wlga presentation
Scrutiny as a critical friend wlga presentationScrutiny as a critical friend wlga presentation
Scrutiny as a critical friend wlga presentation
 
msfhfag
msfhfagmsfhfag
msfhfag
 

Mehr von HTAi Bilbao 2012

How Glaucoma Patients Assess Different Aspects of Their Treatment? An Elicit...
How Glaucoma Patients Assess Different Aspects of Their Treatment?  An Elicit...How Glaucoma Patients Assess Different Aspects of Their Treatment?  An Elicit...
How Glaucoma Patients Assess Different Aspects of Their Treatment? An Elicit...HTAi Bilbao 2012
 
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...HTAi Bilbao 2012
 
Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...HTAi Bilbao 2012
 
The use of ‘colloquial evidence’ in HTA: the experience of NICE
The use of ‘colloquial evidence’ in HTA:  the experience of NICE The use of ‘colloquial evidence’ in HTA:  the experience of NICE
The use of ‘colloquial evidence’ in HTA: the experience of NICE HTAi Bilbao 2012
 
Social values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ens...Social values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ens...HTAi Bilbao 2012
 
Challenges in commissioning research on what works in integrated care
Challenges in commissioning research on what works in integrated careChallenges in commissioning research on what works in integrated care
Challenges in commissioning research on what works in integrated careHTAi Bilbao 2012
 
Building a portfolio of research findings for use by healthcare managers and ...
Building a portfolio of research findings for use by healthcare managers and ...Building a portfolio of research findings for use by healthcare managers and ...
Building a portfolio of research findings for use by healthcare managers and ...HTAi Bilbao 2012
 
Assessing the International Use
Assessing the International Use Assessing the International Use
Assessing the International Use HTAi Bilbao 2012
 
EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...
EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...
EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...HTAi Bilbao 2012
 
On the outside looking in.
On the outside looking in. On the outside looking in.
On the outside looking in. HTAi Bilbao 2012
 
METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...
METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...
METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...HTAi Bilbao 2012
 
How to promote the prescription of evidence-based non-pharmacological treatme...
How to promote the prescription of evidence-based non-pharmacological treatme...How to promote the prescription of evidence-based non-pharmacological treatme...
How to promote the prescription of evidence-based non-pharmacological treatme...HTAi Bilbao 2012
 
The eunethta planned and ongoing projects database
The eunethta planned and ongoing projects databaseThe eunethta planned and ongoing projects database
The eunethta planned and ongoing projects databaseHTAi Bilbao 2012
 
Evaluation of an e health intervention for cancer patients' support
Evaluation of an e health intervention for cancer patients' supportEvaluation of an e health intervention for cancer patients' support
Evaluation of an e health intervention for cancer patients' supportHTAi Bilbao 2012
 
Classification of oecd countries reimbursement systems at the individual tech...
Classification of oecd countries reimbursement systems at the individual tech...Classification of oecd countries reimbursement systems at the individual tech...
Classification of oecd countries reimbursement systems at the individual tech...HTAi Bilbao 2012
 
Bevacizumab for neovascular age related macular degeneration
Bevacizumab for neovascular age related macular degenerationBevacizumab for neovascular age related macular degeneration
Bevacizumab for neovascular age related macular degenerationHTAi Bilbao 2012
 
Azienda ospedaliero Universitaria of Udine
Azienda ospedaliero Universitaria of UdineAzienda ospedaliero Universitaria of Udine
Azienda ospedaliero Universitaria of UdineHTAi Bilbao 2012
 
The application of Health Technology Assessment in the field of biologics: an...
The application of Health Technology Assessment in the field of biologics: an...The application of Health Technology Assessment in the field of biologics: an...
The application of Health Technology Assessment in the field of biologics: an...HTAi Bilbao 2012
 
Hospital-based HTA: does it impact on medical technologies’ expenditure and c...
Hospital-based HTA: does it impact on medical technologies’ expenditure and c...Hospital-based HTA: does it impact on medical technologies’ expenditure and c...
Hospital-based HTA: does it impact on medical technologies’ expenditure and c...HTAi Bilbao 2012
 

Mehr von HTAi Bilbao 2012 (20)

How Glaucoma Patients Assess Different Aspects of Their Treatment? An Elicit...
How Glaucoma Patients Assess Different Aspects of Their Treatment?  An Elicit...How Glaucoma Patients Assess Different Aspects of Their Treatment?  An Elicit...
How Glaucoma Patients Assess Different Aspects of Their Treatment? An Elicit...
 
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...
Transitional Care for Pediatric Patients with Neuromuscular Diseases: A Healt...
 
Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...
 
The use of ‘colloquial evidence’ in HTA: the experience of NICE
The use of ‘colloquial evidence’ in HTA:  the experience of NICE The use of ‘colloquial evidence’ in HTA:  the experience of NICE
The use of ‘colloquial evidence’ in HTA: the experience of NICE
 
Social values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ens...Social values international programme: integrating research and policy to ens...
Social values international programme: integrating research and policy to ens...
 
Challenges in commissioning research on what works in integrated care
Challenges in commissioning research on what works in integrated careChallenges in commissioning research on what works in integrated care
Challenges in commissioning research on what works in integrated care
 
Building a portfolio of research findings for use by healthcare managers and ...
Building a portfolio of research findings for use by healthcare managers and ...Building a portfolio of research findings for use by healthcare managers and ...
Building a portfolio of research findings for use by healthcare managers and ...
 
Assessing the International Use
Assessing the International Use Assessing the International Use
Assessing the International Use
 
EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...
EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...
EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING HEALTHCARE PROFESSIONAL ACCEPT...
 
On the outside looking in.
On the outside looking in. On the outside looking in.
On the outside looking in.
 
METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...
METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...
METHODS, MATHEMATICAL MODELS, DATA QUALITY ASSESSMENT AND RESULT INTERPRETATI...
 
How to promote the prescription of evidence-based non-pharmacological treatme...
How to promote the prescription of evidence-based non-pharmacological treatme...How to promote the prescription of evidence-based non-pharmacological treatme...
How to promote the prescription of evidence-based non-pharmacological treatme...
 
The eunethta planned and ongoing projects database
The eunethta planned and ongoing projects databaseThe eunethta planned and ongoing projects database
The eunethta planned and ongoing projects database
 
Evaluation of an e health intervention for cancer patients' support
Evaluation of an e health intervention for cancer patients' supportEvaluation of an e health intervention for cancer patients' support
Evaluation of an e health intervention for cancer patients' support
 
Classification of oecd countries reimbursement systems at the individual tech...
Classification of oecd countries reimbursement systems at the individual tech...Classification of oecd countries reimbursement systems at the individual tech...
Classification of oecd countries reimbursement systems at the individual tech...
 
Bevacizumab for neovascular age related macular degeneration
Bevacizumab for neovascular age related macular degenerationBevacizumab for neovascular age related macular degeneration
Bevacizumab for neovascular age related macular degeneration
 
Azienda ospedaliero Universitaria of Udine
Azienda ospedaliero Universitaria of UdineAzienda ospedaliero Universitaria of Udine
Azienda ospedaliero Universitaria of Udine
 
HTAi in hospitals
HTAi in hospitalsHTAi in hospitals
HTAi in hospitals
 
The application of Health Technology Assessment in the field of biologics: an...
The application of Health Technology Assessment in the field of biologics: an...The application of Health Technology Assessment in the field of biologics: an...
The application of Health Technology Assessment in the field of biologics: an...
 
Hospital-based HTA: does it impact on medical technologies’ expenditure and c...
Hospital-based HTA: does it impact on medical technologies’ expenditure and c...Hospital-based HTA: does it impact on medical technologies’ expenditure and c...
Hospital-based HTA: does it impact on medical technologies’ expenditure and c...
 

Kürzlich hochgeladen

Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 

Kürzlich hochgeladen (20)

Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 

The views of patients and carers involved in the development of NICE technology appraisals

  • 1. The views of patients and carers involved in the development of NICE technology appraisals Lizzie Amis Patient and Public Involvement Programme National Institute for Health and Clinical Excellence (NICE)
  • 2. Outline of presentation • Patient/carer involvement in the appraisals process • The Patient Expert process at NICE • Patient Expert questionnaire project: – Why we did it – What we did – What we found, including sample comments – Next steps
  • 3. How can patients/carers contribute to a NICE appraisal? • National patient organisations can: – Comment on draft documents – Submit written evidence – Nominate Patient Experts • Individuals can: – Be a lay member on the Appraisal Committee – Attend the committee meeting as a Patient Expert
  • 4. How do Patient Experts contribute? • Attend first Appraisal Committee meeting of each topic • Complete written statement before meeting • Present evidence and comment from patient perspective on: – Experiences and views – Benefits/ advantages of the therapy – Downsides/ concerns of the therapy
  • 5. Why did we do this project? • Surveyed Patient Experts a few years ago (Phase 1) • Made changes based on findings: – ‘Lay Leads’ role – Improved internal processes – Better documentation • Wanted to see whether: – changes had made a difference – there were further possible improvements
  • 6. Patient Expert Questionnaire: what did we do? Phase 1 • Developed a questionnaire asking Patient Experts about their involvement in a NICE appraisal • Piloted the questionnaire • Sent to all Patient Experts who attended a committee meeting between May ’06 and Oct ’07 • Two rounds of chasing for responses Phase 2 • We repeated the process with those who attended (July ‘10 – Dec ‘11) – but using SurveyMonkeyTM
  • 7. Patient Expert Questionnaire: what did we ask about? • About you • Information and support before the day • Practical arrangements and support on the day • Experiences during the committee meeting • After the meeting • What is most important to you? (Phase 2) Text giving explanations • Anything else?
  • 8. What we found 1 – who replied?
  • 9. Who replied? Partial responses 5% [n/a]
  • 10. Who replied – by type of Expert?
  • 11. What we found 2 – Patient Experts’ understanding of the committee meeting
  • 12. Reported understanding of committee questions, presentation and discussion
  • 13. Free text comments – understanding of committee meeting Positive • “The meeting was well organised and well run.” • “There was opportunity to discuss angles of my submission and re-affirm my position on certain aspects.” Concerns • “I felt totally out of my depth and excluded when the technical/statistical information was shared.” • “A lot of the presentation went over my head. There was a lot of discussion [...] which didn’t mean very much to me.”
  • 14. What we found 3 – Patient Experts’ opinions on their involvement in the committee meeting
  • 15. Patient Expert views on their involvement in the committee meeting 24%
  • 16. Comments – Patient involvement in committee meeting Positive • “Felt my presence worthwhile not just tolerated. My contribution listened to with interest. Treated with consideration.” • “I think my comments were taken seriously […] I was given time and opportunity to contribute at several stages of the meeting.” Concerns • “The real issue is whether patients are taken seriously and listened to in the meeting.” • “There was patient experience as far as goes side effects etc, however the patient experience is far more than this...”
  • 17. What we found 4 – What is most important to you?
  • 18. What is considered most important by our patient experts? (Phase 2 only) Ranked in priority order: 1. Having the opportunity to raise the issues I felt relevant 2. Feeling that my contribution made a difference 3. Contact and support before the committee meeting 4. Understanding the committee discussions (A further six criteria were all less important)
  • 19. What we found 5 – Overall experience of committee meeting
  • 20. Overall experience of committee meeting 19%
  • 21. Comments – Overall experience Positive • “I thought it was a very well-thought out process, and feel honoured to have been a part of it.” • “I feel the Patient Expert process works very well. The only improvement would be to have a better understanding of the technology jargon.” Concerns • “The process needs to be made more human and accessible.” • “Patient organisations by and large know how NICE works […] The question is whether NICE […] has developed a similar understanding of patients and patient organisations.”
  • 22. Next Steps • Complete written report • Identify further areas for improvement • Present findings at conferences and in journals • Design exit survey with patients for continual, ongoing monitoring
  • 23. Contact details & more info Lizzie Amis PPIP Programme Manager lizzie.amis@nice.org.uk or +44 (0) 20 7045 2056 Patient and Public Involvement at NICE: http://www.nice.org.uk/getinvolved/patientsandpublic/patientan